Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2mCRPC 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Leukemia 1Extensive Stage Lung Small Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2talazoparib 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1copper dotatate CU-64 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Paraganglioma × talazoparib × Clear all
NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡